We show that breast cancer genomes are rich in predictive and prognostic value. We propose a two-step model for effective clinical application. First, the identification of candidates for targeted therapies or clinical trials using highly individualised genomic markers. Second, for patients without such features, the implementation of enhanced prognostication using genomic features alongside existing clinical decision-making factors.
[Articles] Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysis
The Lancet Oncology | | Daniella Black, Helen Ruth Davies, Gene Ching Chiek Koh, Lucia Chmelova, Marko Cubric, Georgia Chalivelaki Chan, Andrea Degasperi, Jan Czarnecki, Ping Jing Toong, Yasin Memari, James Whitworth, Salome Jingchen Zhao, Yogesh Kumar, Shadi Basyuni, Giuseppe Rinaldi, Scott Shooter, Vladyslav Dembrovskyi, Rosie Davies, Maria Chatzou Dunford, Ellen Copson, Carlo Palmieri, Åke Borg, John Ambrose, Catey Bunce, Alona Sosinsky, Prabhu Arumugam, Matthew Arthur Brown, Johan Staaf, Nicholas Turner, Serena Nik-Zainal
Topics: breast-cancer, clinical-trials, research